首页> 美国卫生研究院文献>Molecular Therapy. Nucleic Acids >NGS-based accurate and efficient detection of circulating cell-free mitochondrial DNA in cancer patients
【2h】

NGS-based accurate and efficient detection of circulating cell-free mitochondrial DNA in cancer patients

机译:基于NGS的癌症患者循环无细胞线粒体DNA的准确有效地检测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mitochondrial DNA (mtDNA) mutations are closely implicated in the pathogenesis of multiple cancers, making circulating cell-free mtDNA (ccf-mtDNA) as a potential non-invasive tumor biomarker. However, an effective approach to comprehensively profile ccf-mtDNA mutations is still lacking. In this study, we first characterized ccf-mtDNA by low-depth whole-genome sequencing (WGS) and found that plasma DNA samples exhibited a dramatic decrease in mtDNA copy number when compared with fresh tumor tissues. Further analysis revealed that plasma ccf-mtDNA had a biased distribution of fragment size with a peak around 90 bp. Based on these insights, we developed a robust captured-based mtDNA deep-sequencing approach that enables accurate and efficient detection of plasma ccf-mtDNA mutations by systematic optimization of probe quantity and length, hybridization temperature, and PCR amplification cycles. Moreover, we found that placement of isolated plasma for 6 h at both 4°C and room temperature (RT) led to a dramatic decrease of ccf-mtDNA stability, highlighting the importance of proper plasma sample processing. We further showed that the optimized approach can successfully detect a substantial fraction of tumor-specific mtDNA mutations in plasma ccf-mtDNA specifically from hepatocellular carcinoma (HCC) patients but not from colorectal cancer (CRC) patients, suggesting the presence of a potential cancer-specific difference in the abundance of tumor-derived mtDNA in plasma.
机译:线粒体DNA(MTDNA)突变与多种癌症的发病机制紧密含义,使无侵袭性肿瘤生物标志物循环无细胞MTDNA(CCF-MTDNA)。然而,仍然缺乏综合性CCF-MTDNA突变的有效方法。在本研究中,我们首先通过低深度全基因组测序(WGS)来表征CCF-MTDNA,并发现与新鲜肿瘤组织相比,血浆DNA样品在MTDNA拷贝数中表现出显着降低。进一步的分析表明,血浆CCF-MTDNA的偏向分布片段大小,峰值约为90bp。基于这些见解,我们开发了一种稳健的基于捕获的MTDNA深序方法,通过系统优化探针数量和长度,杂交温度和PCR扩增循环来准确和有效地检测等离子体CCF-MTDNA突变。此外,我们发现,在4℃和室温(RT)下,在4℃和室温(RT)上放置6小时,导致CCF-MTDNA稳定性的显着降低,突出了适当的等离子体样品处理的重要性。我们进一步表明,优化的方法可以在肝细胞癌(HCC)患者中,成功地检测血浆CCF-MTDNA中的大部分肿瘤特异性MTDNA突变,而不是从结肠直肠癌(CRC)患者,表明存在潜在的癌症 - 血浆中肿瘤衍生MTDNA丰富的特异性差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号